CDH17

Across TCGA pan-cancer cohorts, CDH17 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDH17 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CDH17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDH17 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

CESC, UCEC, and BRCA are the cancer types where CDH17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.142	0.803	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.432	.005	34	view →
BRCA	DFS	Median	All	0.212	0.529	.031	6	view →
LIHC	DFS	Median	All	0.166	0.449	.018	6	view →
BLCA	OS	Median	II,III,IV	0.905	0.409	.034	4	view →
LUSC	DFS	Median	All	1.000	0.384	.036	4	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDH17–CESC (OS)

Open the CESC breakdown →